Professor Morris Brown
Professor Morris Jonathan Brown
MSc, MD, FRCP, FAHA, FMedSci
Professor of Clinical Pharmacology, University of Cambridge;
Honorary Consultant Physician, Cambridge University Hospitals NHS Foundation Trust;
Fellow of Gonville & Caius College, University of Cambridge.
Tel: 01223 336743
Mechanisms of low-renin hypertension. Research is conducted in patients and on the adrenal tissue collected from his patients with adrenal cause of hypertension (Conn's syndrome and phaeochromocytoma). He is leading a British Heart Foundation funded programme of three trials investigating the role of renin measurement in the routine management of hypertension. Other current research projects include evaluation of 11C-metomidate scanning for lateralisation of Conn's adenomas. He was awarded the Lilly Gold Medal of the British Pharmacological Society (2002), and the Walter Somerville Medal of the British Cardiac Society (2006). His introduction of the AB/CD rule, and innovations in management of phaeochromocytoma and Conn's syndrome, led to the Hospital Doctors' Award in 2003. In 2008 he co-hosted the International Symposium on Phaeochromocytoma in Cambridge.
Current Research Support
British Heart Foundation Special Project Grant SP/08/002, A Programme for Prevention And Treatment of Resistant Hypertension With Algorithm based TherapY (PATHWAY). £1,740,984, 1.10.08-30.9.2013, (multicentre award to British Hypertension Society Research Working Party).
British Heart Foundation Project Grant, Hypertension due to Conn's adenoma – the localisation of adrenal cortical adenomas by 11C –metomidate PET scanning following dexamethasone and fludrocortisone suppression. £168,395, 1.12.08-31.3.11.
NIHR, Senior Investigator Award, £60,000, 1.4.08-31.3.2012.
Wellcome Trust, Interdisciplinary Training Programme for Clinicians in Translational Medicine & Therapeutics at the University of Cambridge, £2.75M, 1.1.2009-31.12.2014 (with matching funding from GlaxoSmithKline).
Brown M.J, McInnes G.T, Cherif Papst C., Zhang J., MacDonald T.M.
A randomised, double-blind trial to compare de novo combination with sequential add-on treatment in patients with essential hypertension: Aliskiren and the Calcium Channel BlockEr amLodipine combination as an initial trEatment stRATEgy (ACCELERATE). Lancet, 377: 312-320, 2011.
TJ Burton, G Cope, J Wang, JC Sim, EAB Azizan, KM O'Shaughnessy and MJ Brown.
Expression of the epithelial Na+ channel and other components of an aldosterone response pathway in human adrenalocortical cells. European Journal of Pharmacology, 613, issues 1-3: 176-181, 2009.
The impact of clinical trials legislation on clinical pharmacology: problems and solutions. British Journal of Clincial Pharmacology 67(5):487-493, 2009.
Brown MJ and Toal CB.
Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients. Br J Clin Pharmacol.65:646-52, 2008.
Renin: friend or foe? Heart, 93: 1026-1033, 2007.
Siva A, De Lange M, Clayton D, Monteith S, Spector TD and Brown M.
Heritability of plasma homocysteine, and influence of genetic variation in the homocysteine methylation pathway. QJM, 100: 495-499, 2007.
Mackenzie IS, Gurnell M, Balan KK, Simpson H, Chatterjee K and Brown MJ.
The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. European Journal of Endocrinology, 157:533-537, 2007.
Hood SJ, Taylor K and Brown MJ.
The Spironolactone, Amiloride, Losartan and Thiazide (SALT) double-blind crossover trial in patients with low- renin hypertension and elevated aldosterone/renin ratio. Circulation 116: 268-275, 2007.
Sharma, Pankaj; Middelberg, Rita PS; Andrew, Toby; Johnson, Michael R; Christley, Howard; Brown, Morris J.
Heritability of left ventricular mass in a large cohort of twins. Journal of Hypertension: Volume 24(2)February 2006 p 321-324
Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, & Wilkinson IB (2006).
Atenolol and Eprosartan: Differential Effects on Central Blood Pressure and Aortic Pulse Wave Velocity. Am J Hypertens 19, 214-219.
Brown MJ, Mackenzie, IS, Ashby MJ, Balan KK, Appleton DS.
AT2 receptor stimulation may halt progression of phaeochromocytoma. Ann NY Acad Sci: 1073: 436-443, 2006.
Hypertension and ethnic group. British Medical Journal, 332:833-836, 2006.
Padmanabhan S, Wallace C, Munroe PB, Dobson R, Brown MJ et al.
Chromosome 2p shows significant linkage to antihypertensive response in the British Genetics of Hypertension Study. Hypertension: 47:603-8, 2006.
Newhouse SJ, Wallace C, Dobson R, et al.
Haplotypes of the WNK1 gene associate with blood pressure variation in a severely hypertensive population from the British Genetics of Hypertension study. Hum Mol Genet;14:1805-14, 2005.
Mackenzie IS, Maki-Petaja KM, McEniery CM, et al.
Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler Thromb Vasc Biol;25:1891-5, 2005
Sandilands AJ, Parameshwar J, Large S, Brown MJ and O’Shaughnessy KM.
Confirmation of a role for the 389R>G b-1 adrenoceptor polymorphism on exercise capacity in heart failure. Heart: 91: 1613-1614, 2005.
Blood Pressure Lowering Treatment Triallists Collaboration.
Effects of different blood pressure-lowering regiments on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med, 165:1410-1419, 2005.
Hood S, Foo R, Cannon J, Brown MJ.
Prevalence of primary hyperaldosteronism assessed by aldosterone to renin ratio and spironolactone testing. Clin Med, 5:55-60, 2005.
Lewis CJ, Gong H, Brown MJ and Harding SE.
Overexpression of b1-adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A cardiostimulation: implications for “putative” b4-adrenoceptor pharmacology. Br J Pharmacol, 141(5):813-24, 2004.
Neal DA, Brown MJ, Wilkinson IB, Byrne CD, Alexander GJ.
Hemodynamic effects of amlodipine, bisoprolol and lisinopril in hypertensive patients after liver transplantation. Transplantation, 15:77(5):748-50:2004